What is Uramustin used for?

Uramustin is indicated for Chronic lymphoid leukemia, disease, Chronic myeloid leukemia, Non-Hodgkin's lymphoma, Polycythemia vera.

What development phase is Uramustin in?

Uramustin is FDA-approved (marketed).

What is the generic name of Uramustin?

URACIL MUSTARD is the generic (nonproprietary) name of Uramustin.

Last reviewed 2026-04-20 · How we verify

Uramustin (URACIL MUSTARD)

FDA-approved approved Small molecule Quality 20/100

At a glance

Generic name	URACIL MUSTARD
Drug class	uracil mustard
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved
First approval	1962

Approved indications

Chronic lymphoid leukemia, disease
Chronic myeloid leukemia
Non-Hodgkin's lymphoma
Polycythemia vera

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (PHASE1,PHASE2)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (PHASE2)
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (PHASE2)
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer (PHASE2)
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (PHASE3)
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Uramustin CI brief — competitive landscape report
Uramustin updates RSS · CI watch RSS